TAIJI GROUP(SH:600129) EBSCN·2026-03-12 14:10Investment Rating - The report assigns a rating of "Accumulate" to the company, reflecting a downward adjustment from previous ratings [4][6]. Core Insights - The company is expected to experience a significant rebound in its operating performance, with a projected net profit of approximately 110 million yuan for 2025, representing a year-on-year increase of about 313% [4]. - The company is focusing on its core pharmaceutical business while enhancing management efficiency and innovation through the disposal of non-core assets and subsidiaries [3][4]. - Recent policies promoting the development of traditional Chinese medicine are anticipated to benefit leading companies in the industry, enhancing compliance and quality control [2]. Summary by Sections Company Overview - The company is undergoing a transformation by divesting non-core assets and subsidiaries, including the liquidation of certain subsidiaries and the management of stakes in other companies [3]. Financial Performance - The company forecasts a net profit of 110 million yuan for 2025, with a significant increase in net profit margin expected [4]. - The anticipated non-recurring gains of approximately 62 million yuan will impact the overall financial results [4]. Market Position and Strategy - The company is committed to innovation in both technology and marketing, aiming to strengthen its industrial marketing system and enhance product development [3]. - The focus on core competencies and operational efficiency is expected to stabilize and improve the company's market position [4]. Future Outlook - The company is projected to return to a growth trajectory, with net profit estimates for 2026 and 2027 at 213 million yuan and 377 million yuan, respectively [4]. - The ongoing reforms in the healthcare sector and the reduction of social inventory for certain products are expected to positively influence sales and revenue in the coming years [4].